MediciNova (MNOV) Stock Price, News & Analysis

Company Overview

MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neurological, inflammatory, and fibrotic diseases. The company does not currently market an approved product in the United States and instead advances candidates through clinical development and regulatory evaluation.

Its lead compound, MN-166 (ibudilast), is being investigated for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance-use disorders. Ibudilast has previously been approved in Japan and China for certain respiratory and cerebrovascular conditions, although MediciNova is evaluating the compound for additional indications. The company has also developed MN-001 (tipelukast), an oral therapy studied for diseases involving fibrosis and inflammation, including nonalcoholic steatohepatitis and pulmonary fibrosis.

MediciNova was founded in 2000 and is headquartered in La Jolla, California. The company conducts development activities through collaborations and clinical studies in the United States and internationally, with a particular historical connection to Japan. MediciNova is led by Yuichi Iwaki, M.D., Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.67 to $1.84
• 50-Day Range: $1.29 to $3.45
• 52-Week Range: $1.17 to $3.90
• Volume: 274,502 shs
• Average Volume: 915,765 shs
• Market Capitalization: $87.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Moderate Buy

MediciNova Stock Analysis - MarketRank™

MediciNova scored higher than 54% of companies evaluated by MarketBeat, and ranked 435th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MediciNova has a consensus price target of $7.75, representing about 335.4% upside from its current price of $1.78.

Amount of Analyst Coverage

MediciNova has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MediciNova are expected to decrease in the coming year, from ($0.25) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediciNova is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediciNova is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediciNova has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.89% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 4.27.

Change versus previous month

Short interest in MediciNova has recently increased by 1.35%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediciNova does not currently pay a dividend.

Dividend Growth

MediciNova does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.19

News Sentiment

MediciNova has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for MediciNova this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for MNOV on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

1 people have added MediciNova to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,000.00 in company stock.

Percentage Held by Insiders

14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.90% of the stock of MediciNova is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MNOV
• CIK: 1226616
• Web: medicinova.com
• Phone: (858) 373-1500
• Fax: 858-404-0048
• Employees: 6
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MediciNova: $7.75
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +335.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12 million
• Net Margins: -1,168.70%
• Pretax Margin: -1,168.15%
• Return on Equity: -26.51%
• Return on Assets: -24.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.75
• Quick Ratio: 8.75

Sales & Book Value

• Annual Sales: $410 thousand
• Price / Sales: 213.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 49,220,000
• Free Float: 42,330,000
• Market Cap: $87.61 million
• Optionable: Optionable
• Beta: 0.61